Videos

Panelists discuss how the DSM-5-TR criteria for ADHD require at least 6 of 9 symptoms in either inattentive or hyperactive-impulsive domains, with inattentive presentations often going unrecognized especially in females and highly intelligent students.

Panelists discuss how ADHD presents in a 10-year-old boy with combined presentation symptoms, emphasizing the importance of seeing difficulties across multiple settings and noting the genetic component when family history is present.

"It all depends on the child’s arrival..."

Explore best practices in child mental health through real case studies in the DSM-5-TR Casebook and Treatment Guide for Child Mental Health, featuring expert insights and treatment strategies.

Learn more from 30 case examples in the new book, DSM-5-TR Casebook and Treatment Guide for Child Mental Health.

H. Steven Moffic, MD, ponders the interesting story behind the Goldwater Rule, and whether it remains useful as is.

The DSM-5-TR Casebook and Treatment Guide for Child Mental Health provides a wide array of cases to instruct clinicians on the best practices for treating child and adolescent mental health problems.

The RECOVER open label trial demonstrated positive results for brilaroxazine for schizophrenia.

Busy Philipps and Ann Childress, MD, explore the unique challenges women face in ADHD diagnosis, highlighting personal stories and the importance of treatment.

Discover essential insights for diagnosing and treating child mental health issues in the DSM-5-TR Casebook and Treatment Guide for Child Mental Health, a vital resource for clinicians.

"The jackrabbit is a mild herbivore grazing the desert floor, quietly abridging spring..."

Are we ready yet to give peace a chance?

Phillip R. Muskin, MD, discusses the complexities of prescribing antipsychotics, emphasizing patient collaboration and the importance of evaluating treatment strategies.

"There are a million birds in this city I hadn’t heard till now, each of them tuning their instruments, each of them singing, I am alive."

Take a look at innovative GSK-3β inhibitors to enhance efficacy and reduce adverse effects seen in lithium with Jonathan M. Meyer, MD, DLFAPA, at the 2025 APA Annual Meeting.

How many apps do you use on your phone? John Luo, MD, a technology expert shares his thoughts on their usefulness at the 2025 APA Annual Meeting.

Ketamine-assisted psychotherapy: enhancing healing through emotional support and insight-driven therapy for depression.

Psychiatry must embrace media to combat misinformation, shared Mena Mirhom, MD, FAPA, at the 2025 APA Annual Meeting.

Will AI replace psychiatrists and mental health clinicians? John Luo, MD, thinks not, despite the many technological advances of today.

Badr Ratnakaran, MBBs, highlights the rising stressors for older adults, emphasizing the urgent need for improved health care and support systems.

Fathers share their heartbreaking stories of loss and advocate for a new model of suicide prevention that emphasizes early intervention and awareness at the 2025 APA Annual Meeting.

Discover how insulin influences mood and cognition, revealing new therapeutic possibilities for depression and bipolar disorder, in this discussion with Roger McIntyre, MD, FRCPC, at the 2025 APA Annual Meeting.

Experts discuss groundbreaking insights on ketamine's role in treating depression, highlighting its rapid effects and potential to transform psychopharmacology.

Why was this year's APA Annual Meeting historic? H. Steven Moffic, MD, shares his thoughts.

How does adult ADHD differ from pediatric ADHD? Jeffrey Newcorn, MD, shared his expertise at the 2025 APA Annual Meeting.

The APA Annual Meeting: a valuable career opportunity.

At the APA Annual Meeting, John Luo, MD, discussed the importance of managing your online reputation and privacy in today's digital landscape for future opportunities.

Antipsychotic plasma levels play a critical role of in treatment decisions. Learn more in this conversation from the 2025 APA Annual Meeting.